Finanzen von Akoya Biosciences Inc (AKYA)AKYAAkoya Biosciences Inc

Akoya Biosciences Inc (AKYA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Service and other revenue, accounting for 34.6% of total sales, equivalent to $6.52M. Other significant revenue streams include Consumables and Instruments. Understanding this composition is critical for investors evaluating how AKYA navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Akoya Biosciences Inc maintains a gross margin of 59.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -79.73%, while the net margin is -94.07%. These profitability ratios, combined with a Return on Equity (ROE) of -354.27%, provide a clear picture of how effectively AKYA converts its operational activities into shareholder value.

In the context of the broader market, AKYA competes directly with industry leaders such as INMB and ZURA. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, AKYA's gross margin of 59.32% stands against INMB's N/A and ZURA's N/A. Such benchmarking helps identify whether Akoya Biosciences Inc is trading at a premium or discount relative to its financial performance.